person · Reporting owner

HAYDEN DONALD J JR

Disclosed activity across 6 companies

Tapewire entity: 17557
SEC CIK: 0001202285

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
AMICUS THERAPEUTICS, INC.FOLD · Entity 51196	Director	June 07, 2018	June 11, 2018
BRISTOL MYERS SQUIBB CO(BMY) · Entity 1662	EVP and President, Americas	March 01, 2005	March 03, 2005
INSMED IncINSM · Entity 3174	Director	April 09, 2019	April 11, 2019
REGENXBIO Inc.RGNX · Entity 2211	Director	May 29, 2020	June 02, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

AMICUS THERAPEUTICS, INC.

Report date June 07, 2018 · Filed June 11, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,895	Reported balance After 2018-06-07 transaction · row 1 1 source row Row 1 · 2018-06-07 · Grant · Acquired 3,081 · Balance 8,895 F1: The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics, Inc. common Stock.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.23 · Expires 2028-06-07	Direct	8,912	Reported balance After 2018-06-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-06-07 · Grant · Acquired 8,912 · Balance 8,912 F2: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2019.

Filing footnotes · ownership attribution and instrument terms

F1: The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics, Inc. common Stock.

F2: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2019.

BRISTOL MYERS SQUIBB CO

Report date March 01, 2005 · Filed March 03, 2005

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.10 par valueSEC Table I · non-derivative	Direct	207,649	Reported balance After 2005-03-01 transaction · row 1 1 source row Row 1 · 2005-03-01 · Grant · Acquired 16,667 · Balance 207,649 F1: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.
Executive Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.45 · Expires 2015-02-28	Direct	100,000	Reported balance After 2005-03-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2005-03-01 · Grant · Acquired 100,000 · Balance 100,000 F3: Option is not exercisable until the earlier of (i) the closing share price of common stock achieving a price of at least 15% above the option grant price and remaining at that price for seven consecutive trading days or (ii) the ninth anniversary of the grant date. Shares underlying option vest 25% a year, on a cumulative basis, commencing one year after the date of grant.
Common Stock, $0.10 par valueSEC Table I · non-derivative	IndirectBy BMY Savings & Investment Program	4,869.72	Reported balance Holding disclosure · report date 2005-03-01 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 4,869.72 F2: Based on a plan statement as of the end of the most recent fiscal quarter.

Filing footnotes · ownership attribution and instrument terms

F1: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date.

F2: Based on a plan statement as of the end of the most recent fiscal quarter.

F3: Option is not exercisable until the earlier of (i) the closing share price of common stock achieving a price of at least 15% above the option grant price and remaining at that price for seven consecutive trading days or (ii) the ninth anniversary of the grant date. Shares underlying option vest 25% a year, on a cumulative basis, commencing one year after the date of grant.

INSMED Inc

Report date April 09, 2019 · Filed April 11, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	62,197	Ending reported balance After 2019-04-09 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2019-04-09 · Exercise / conversion · Acquired 6,286 · Balance 68,483 F1: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 2 · 2019-04-09 · Sale · Disposed 6,286 · Balance 62,197 F1: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.03 · Expires 2021-12-21	Direct	3,714	Reported balance After 2019-04-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-04-09 · Exercise / conversion · Disposed 6,286 · Balance 3,714 F2: Stock options granted on December 21, 2011 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each six month anniversary date thereafter through the fourth anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2: Stock options granted on December 21, 2011 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each six month anniversary date thereafter through the fourth anniversary of the date of grant.

REGENXBIO Inc.

Report date May 29, 2020 · Filed June 02, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.66 · Expires 2030-05-29	Direct	10,000	Reported balance After 2020-05-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-05-29 · Grant · Acquired 10,000 · Balance 10,000 F1: The option will vest in 12 equal monthly installments following May 29, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The option will vest in 12 equal monthly installments following May 29, 2020.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Theseus Pharmaceuticals, Inc.

Report date February 14, 2024 · Filed February 14, 2024

Section 16 reporting ended · disclosed 2024-02-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2024-02-14 transaction · row 1 1 source row Row 1 · 2024-02-14 · Other · Disposed 10,000 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger. F2: At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $4.05 per Share in cash (the "Cash Amount"), subject to any applicable withholding taxes and without interest, plus (b) one non-transferable contractual contingent value right per Share (each, a "CVR"), which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-02-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-02-14 · Disposition to issuer · Disposed 3,250 · Balance 0 F3: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share. F4: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger.

F2: At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $4.05 per Share in cash (the "Cash Amount"), subject to any applicable withholding taxes and without interest, plus (b) one non-transferable contractual contingent value right per Share (each, a "CVR"), which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal.

F3: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share.

F4: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU.

Vitae Pharmaceuticals, Inc

Report date October 25, 2016 · Filed October 25, 2016

Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.29 · Expires 2024-06-24	Direct	Reported balance After 2016-10-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2016-10-25 · Disposition to issuer · Disposed 18,182 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F2: This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2024-09-23	Direct	Reported balance After 2016-10-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2016-10-25 · Disposition to issuer · Disposed 17,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.43 · Expires 2025-05-27	Direct	Reported balance After 2016-10-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-10-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F4: This option, which is fully vested was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.62 · Expires 2026-05-25	Direct	Reported balance After 2016-10-25 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-10-25 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F5: This option, which provided for vesting in four (4) equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.

F2: This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

F3: This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

F4: This option, which is fully vested was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

F5: This option, which provided for vesting in four (4) equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 14, 2024 Filed Feb 14, 2024 16:01 UTC	Theseus Pharmaceuticals, Inc. THRX · Entity 94301	Disposition to issuerRestricted Stock Units · Derivative	3,250	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-023563 · tm246087-4_4seq1.xml · derivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,250 shares Expires not disclosed F3 · derivative.exercise_price: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share. F4 · price: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU. F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) the Cash Amount, without interest and subject to any withholding of taxes; and (ii) one CVR for each Share subject to such Issuer RSU. Read SEC document
February 14, 2024 Filed Feb 14, 2024 16:01 UTC	Theseus Pharmaceuticals, Inc. THRX · Entity 94301	OtherCommon Stock	10,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-24-023563 · tm246087-4_4seq1.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger. F2 · price: At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $4.05 per Share in cash (the "Cash Amount"), subject to any applicable withholding taxes and without interest, plus (b) one non-transferable contractual contingent value right per Share (each, a "CVR"), which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. Read SEC document
June 13, 2023 Filed Jun 13, 2023 17:29 UTC	Theseus Pharmaceuticals, Inc. THRX · Entity 94301	GrantRestricted Stock Unit · Derivative	3,250	$0.00	$0.00	Disclosure SEC source: 0001745020-23-000037 · wk-form4_1686691764.xml · derivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,250 Underlying: Common Stock · 3,250 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001 per share, when vested. F3 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 9, 2024 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 9, 2024 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date. The RSUs have no expiration date. Read SEC document
June 13, 2023 Filed Jun 13, 2023 17:29 UTC	Theseus Pharmaceuticals, Inc. THRX · Entity 94301	GrantStock Option (right to buy) · Derivative	19,500	$0.00 Strike: $9.61	$0.00	Disclosure SEC source: 0001745020-23-000037 · wk-form4_1686691764.xml · derivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2033-06-12 F1 · derivative.exercise_date: The options are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 9, 2024 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date. Read SEC document
December 30, 2022 Filed Jan 3, 2023 07:05 UTC	Theseus Pharmaceuticals, Inc. THRX · Entity 94301	PurchaseCommon Stock	9,900	$5.00	$49,489.11	Disclosure SEC source: 0001104659-23-000080 · tm2233814-1_4seq1.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported is a weighted average price of shares purchased. These shares were purchased in multiple transactions at prices ranging from $4.98 to $5.00, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document
December 29, 2022 Filed Jan 3, 2023 07:05 UTC	Theseus Pharmaceuticals, Inc. THRX · Entity 94301	PurchaseCommon Stock	100	$5.00	$500.00	Disclosure SEC source: 0001104659-23-000080 · tm2233814-1_4seq1.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Read SEC document
May 17, 2022 Filed May 18, 2022 16:27 UTC	Theseus Pharmaceuticals, Inc. THRX · Entity 94301	GrantStock Option (right to buy) · Derivative	60,000	$0.00 Strike: $8.02	$0.00	Disclosure SEC source: 0000899243-22-018615 · doc4.xml · derivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2032-05-17 F1 · derivative.exercise_date: The options are subject to a service-based vesting requirement, which shall be satisfied over a three-year period with 1/36th of the options vesting on June 17, 2022 and 1/36th of the options vesting monthly thereafter, subject to the Reporting Person's continuous service with the issuer on each such vesting date. Read SEC document
May 29, 2020 Filed Jun 2, 2020 16:34 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $37.66	$0.00	Disclosure SEC source: 0001562180-20-004066 · primarydocument.xml · derivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-05-29 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 29, 2020. Read SEC document
February 10, 2020 Filed Feb 12, 2020 16:22 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	24,800	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001562180-20-001108 · primarydocument.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,100 Underlying: Common Stock · 24,800 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares vested each month thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document
February 10, 2020 Filed Feb 12, 2020 16:22 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	24,800	$50.11	$1,242,728.00	Disclosure SEC source: 0001562180-20-001108 · primarydocument.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 10, 2020 Filed Feb 12, 2020 16:22 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	24,800	$0.85	$21,080.00	Disclosure SEC source: 0001562180-20-001108 · primarydocument.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 05, 2020 Filed Feb 7, 2020 16:19 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	2,000	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001562180-20-001013 · primarydocument.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,900 Underlying: Common Stock · 2,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares vested each month thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document
February 05, 2020 Filed Feb 7, 2020 16:19 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	2,000	$50.00	$100,000.00	Disclosure SEC source: 0001562180-20-001013 · primarydocument.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 05, 2020 Filed Feb 7, 2020 16:19 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	2,000	$0.85	$1,700.00	Disclosure SEC source: 0001562180-20-001013 · primarydocument.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
January 17, 2020 Filed Jan 21, 2020 16:16 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	3,200	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001562180-20-000452 · primarydocument.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,900 Underlying: Common Stock · 3,200 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares vested each month thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document
January 17, 2020 Filed Jan 21, 2020 16:16 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	3,200	$50.01	$160,032.00	Disclosure SEC source: 0001562180-20-000452 · primarydocument.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
January 17, 2020 Filed Jan 21, 2020 16:16 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	3,200	$0.85	$2,720.00	Disclosure SEC source: 0001562180-20-000452 · primarydocument.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
January 14, 2020 Filed Jan 16, 2020 16:18 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001562180-20-000391 · primarydocument.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,100 Underlying: Common Stock · 30,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares vested each month thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document
January 14, 2020 Filed Jan 16, 2020 16:18 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	30,000	$45.60	$1,368,000.00	Disclosure SEC source: 0001562180-20-000391 · primarydocument.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.00 to $45.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
January 14, 2020 Filed Jan 16, 2020 16:18 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	30,000	$0.85	$25,500.00	Disclosure SEC source: 0001562180-20-000391 · primarydocument.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
May 31, 2019 Filed Jun 4, 2019 16:21 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $43.02	$0.00	Disclosure SEC source: 0001562180-19-003293 · primarydocument.xml · derivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-31 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2019. Read SEC document
April 09, 2019 Filed Apr 11, 2019 20:06 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionStock Option (right to buy) · Derivative	6,286	$0.00 Strike: $3.03	$0.00	Disclosure SEC source: 0001127430-19-000045 · edgar.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,714 Underlying: Common Stock · 6,286 shares Expires 2021-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock options granted on December 21, 2011 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each six month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document
April 09, 2019 Filed Apr 11, 2019 20:06 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	6,286	$32.99	$207,375.14	Disclosure SEC source: 0001127430-19-000045 · edgar.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,197 F1 · kind: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
April 09, 2019 Filed Apr 11, 2019 20:06 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionCommon Stock	6,286	$3.03	$19,046.58	Disclosure SEC source: 0001127430-19-000045 · edgar.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
February 22, 2019 Filed Feb 26, 2019 21:07 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionStock Option (right to buy) · Derivative	14,900	$0.00 Strike: $3.03	$0.00	Disclosure SEC source: 0001127430-19-000035 · edgar.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 Underlying: Common Stock · 14,900 shares Expires 2021-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock options granted on December 21, 2011 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each six month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document
February 22, 2019 Filed Feb 26, 2019 21:07 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	14,900	$28.08	$418,392.00	Disclosure SEC source: 0001127430-19-000035 · edgar.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,197 F1 · kind: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
February 22, 2019 Filed Feb 26, 2019 21:07 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionCommon Stock	14,900	$3.03	$45,147.00	Disclosure SEC source: 0001127430-19-000035 · edgar.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
February 15, 2019 Filed Feb 27, 2019 21:08 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionStock Option (right to buy) · Derivative	100	$0.00 Strike: $3.03	$0.00	Disclosure SEC source: 0001127430-19-000041 · edgar.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,900 Underlying: Common Stock · 100 shares Expires 2021-12-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Stock options granted on December 21, 2011 under the Company's 2000 Stock Incentive Plan. The options became exercisable based on the following vesting schedule: twenty five percent (25%) on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each six month anniversary date thereafter through the fourth anniversary of the date of grant. F3 · balance_after: Total does not reflect previously reported transactions that occurred after February 15, 2019. This report has been filed late due to a broker reporting error. Read SEC document
February 15, 2019 Filed Feb 27, 2019 21:08 UTC	INSMED Inc INSM · Entity 3174	SaleCommon Stock	100	$27.90	$2,790.00	Disclosure SEC source: 0001127430-19-000041 · edgar.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,197 F1 · kind: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
February 15, 2019 Filed Feb 27, 2019 21:08 UTC	INSMED Inc INSM · Entity 3174	Exercise / conversionCommon Stock	100	$3.03	$303.00	Disclosure SEC source: 0001127430-19-000041 · edgar.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document
June 07, 2018 Filed Jun 11, 2018 20:44 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	8,912	$0.00 Strike: $16.23	$0.00	Disclosure SEC source: 0001209191-18-036997 · doc4.xml · derivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,912 Underlying: Common Stock · 8,912 shares Expires 2028-06-07 F2 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2019. Read SEC document
June 07, 2018 Filed Jun 11, 2018 20:44 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	3,081	$0.00	$0.00	Disclosure SEC source: 0001209191-18-036997 · doc4.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,895 F1 · shares: The Restricted Stock Units will vest one year after date of grant and vested shares will be payable in common stock. One (1) Restricted Stock Unit is the equivalent of one (1) share of Amicus Therapeutics, Inc. common Stock. Read SEC document
June 05, 2018 Filed Jun 5, 2018 17:40 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	14,900	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001562180-18-002884 · primarydocument.xml · derivative · entry 6 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,100 Underlying: Common Stock · 14,900 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares shall vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. Read SEC document
June 05, 2018 Filed Jun 5, 2018 17:40 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	14,900	$55.01	$819,649.00	Disclosure SEC source: 0001562180-18-002884 · primarydocument.xml · nonDerivative · entry 4 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $55.00 to $55.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 05, 2018 Filed Jun 5, 2018 17:40 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	14,900	$0.85	$12,665.00	Disclosure SEC source: 0001562180-18-002884 · primarydocument.xml · nonDerivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
June 01, 2018 Filed Jun 5, 2018 17:40 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	100	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001562180-18-002884 · primarydocument.xml · derivative · entry 5 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,000 Underlying: Common Stock · 100 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares shall vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. Read SEC document
June 01, 2018 Filed Jun 5, 2018 17:40 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	100	$55.00	$5,500.00	Disclosure SEC source: 0001562180-18-002884 · primarydocument.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
June 01, 2018 Filed Jun 5, 2018 17:40 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	100	$0.85	$85.00	Disclosure SEC source: 0001562180-18-002884 · primarydocument.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
May 25, 2018 Filed May 30, 2018 16:30 UTC	REGENXBIO Inc. RGNX · Entity 2211	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $49.45	$0.00	Disclosure SEC source: 0001562180-18-002716 · primarydocument.xml · derivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-25 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 25, 2018. Read SEC document
May 15, 2018 Filed May 16, 2018 16:15 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	9,847	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001562180-18-002518 · primarydocument.xml · derivative · entry 6 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,100 Underlying: Common Stock · 9,847 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares shall vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. Read SEC document
May 15, 2018 Filed May 16, 2018 16:15 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	9,847	$50.06	$492,940.82	Disclosure SEC source: 0001562180-18-002518 · primarydocument.xml · nonDerivative · entry 4 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 15, 2018 Filed May 16, 2018 16:15 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	9,847	$0.85	$8,369.95	Disclosure SEC source: 0001562180-18-002518 · primarydocument.xml · nonDerivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,847 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
May 15, 2018 Filed May 17, 2018 20:14 UTC	INSMED Inc INSM · Entity 3174	GrantCommon Stock	6,066	Not disclosed	Not disclosed	Disclosure SEC source: 0001127430-18-000040 · edgar.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,197 F1 · shares: The Restricted Stock Units have a one year cliff vesting period, provided that the director (a) remains a member of the Board on such vesting date, and (b) attends at least 75% of the meetings of the Board which take place between the grant date and the first anniversary of the grant date. Vested shares are delivered within 30 days of vesting date. F2 · price: Each Restricted Stock Unit was granted on May 15, 2018, and represents a contingent right to receive one share of Common Stock. Read SEC document
May 14, 2018 Filed May 16, 2018 16:15 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	5,153	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001562180-18-002518 · primarydocument.xml · derivative · entry 5 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,947 Underlying: Common Stock · 5,153 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares shall vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. Read SEC document
May 14, 2018 Filed May 16, 2018 16:15 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	5,153	$50.04	$257,856.12	Disclosure SEC source: 0001562180-18-002518 · primarydocument.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $50.00 to $50.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
May 14, 2018 Filed May 16, 2018 16:15 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	5,153	$0.85	$4,380.05	Disclosure SEC source: 0001562180-18-002518 · primarydocument.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
May 09, 2018 Filed May 11, 2018 16:17 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $0.85	$0.00	Disclosure SEC source: 0001562180-18-002456 · primarydocument.xml · derivative · entry 3 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,100 Underlying: Common Stock · 15,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 354,100 shares, became exercisable as follows: 237,269 of the shares subject to the option are initial shares ("Initial Shares") and 116,831 of the shares subject to the option are contingent shares ("Contingent Shares"). 60,197 of the Initial Shares vested on September 17, 2014, 44,268 of the Initial Shares vested on September 17, 2015 and an additional 3,689 of the Initial Shares shall vest upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vest over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares vesting in 36 equal monthly installments thereafter. Read SEC document
May 09, 2018 Filed May 11, 2018 16:17 UTC	REGENXBIO Inc. RGNX · Entity 2211	SaleCommon Stock	15,000	$45.00	$675,000.00	Disclosure SEC source: 0001562180-18-002456 · primarydocument.xml · nonDerivative · entry 2 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
May 09, 2018 Filed May 11, 2018 16:17 UTC	REGENXBIO Inc. RGNX · Entity 2211	Exercise / conversionCommon Stock	15,000	$0.85	$12,750.00	Disclosure SEC source: 0001562180-18-002456 · primarydocument.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
January 02, 2018 Filed Jan 4, 2018 22:08 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	10,000	$0.00 Strike: $10.53	$0.00	Disclosure SEC source: 0001209191-18-002047 · doc4.xml · derivative · entry 4 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2017. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.